Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension

PHASE3CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 24, 2018

Primary Completion Date

April 8, 2024

Study Completion Date

May 8, 2024

Conditions
XIAP DeficiencyNLRC4-MAS
Interventions
DRUG

Tadekinig alfa

Open label, 26 weeks on Tadekinig alfa treatment.

Trial Locations (11)

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children Hospital of Philadelphia, Philadelphia

30322

Children's Healthcare of Atlanta at Egleston, Atlanta

32610

Shands Children's Hospital, Gainsville

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

77030

Texas Children's Hospital _ Baylor College of Medicine, Houston

79106

Universitätsklinikum Freiburg, Centrum für Chronische Immundefizienz (CCI) - Paediatric Unit, Freiburg im Breisgau

92056

UCSD _ Department of Pediatrics / Rady Children's Hospital, La Jolla

02115

Boston Children's Hospital, Boston

ON M5G 1X8

The Hospital for Sick Children, Toronto

Unknown

CHU Sainte-Justine, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AB2 Bio Ltd.

INDUSTRY